Welcome to our dedicated page for BioNxt Solutions news (Ticker: BNXTF), a resource for investors and traders seeking the latest updates and insights on BioNxt Solutions stock.
BioNxt Solutions Inc. (BNXTF) is a bioscience innovator developing advanced drug delivery platforms for autoimmune and neurological conditions. This page serves as the definitive source for verified corporate announcements, research milestones, and strategic developments.
Investors and industry observers will find timely updates on BioNxt’s sublingual thin-film technologies, transdermal delivery systems, and regulatory progress across global markets. Key updates include partnership agreements with European CRDMOs, intellectual property filings, and clinical pipeline advancements targeting conditions like multiple sclerosis and lupus nephritis.
All content undergoes strict verification to ensure accuracy and relevance. Regular updates cover:
• Strategic collaborations with pharmaceutical partners
• Regulatory submissions and quality compliance achievements
• Product development milestones in drug delivery innovation
• Intellectual property portfolio expansions
Bookmark this page for direct access to BioNxt’s official communications and analyzed market developments. For comprehensive investment research, combine these updates with SEC filings and financial disclosures.
BioNxt Solutions has signed a master services agreement (MSA) with a German international contract research, development, and manufacturing organization (CRDMO) to advance its pipeline of oral dissolvable (ODF) drug formulations.
The CRDMO, based in Munich, Germany, offers certified services and manufacturing capabilities across five countries. BioNxt aims to leverage this agreement to progress its proprietary ODF Cladribine dosage form for the multiple sclerosis (MS) market.
Cladribine tablets, already approved in over 75 countries, including by the FDA and EMA, have annual sales exceeding $1 billion. BioNxt plans to file additional patent applications for Cladribine ODF by early 2025, potentially extending patent protection to 2044.
This agreement facilitates BioNxt's regulatory, technical, and laboratory needs, setting the stage for a human comparative bioequivalence study.
BioNxt Solutions announced the closure of the second tranche of its non-brokered private placement, issuing 1,000,000 common shares at $0.27 each, raising $270,000.
The overall offering aims to issue a maximum of 6,000,000 shares to gather up to $1,620,000. Net proceeds will fund research, development, commercialization, and general working capital.
The company paid $21,600 in cash finder's fees and issued 80,000 non-transferable Common Share purchase warrants, exercisable at $0.36 per share for 24 months.
Securities issued are subject to a statutory hold period of four months plus a day.
FAQ
What is the current stock price of BioNxt Solutions (BNXTF)?
What is the market cap of BioNxt Solutions (BNXTF)?
